STOUGHTON, Mass. , July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and provide

STOUGHTON, Mass. , June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best Places to Work.

– Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 – – Non-GAAP Net Income of $31.2 Million in the First Quarter of 2020 – – Xtampza ® ER Prescriptions Grew 30% Over the First Quarter of 2019 – – Collegium Updates 2020 Guidance to Reflect COVID-19 Impact – –

STOUGHTON, Mass. , April 23, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and provide a

STOUGHTON, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in April: The

– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza ® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Feb. 27, 2020 (GLOBE NEWSWIRE) --   Collegium

STOUGHTON, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, confirmed today the details of the year-end earnings call, previously announced on February 13, 2020 .

– Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option – – Collegium will Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and Provide Corporate Update – STOUGHTON, Mass. , Feb.

STOUGHTON, Mass. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities

STOUGHTON, Mass. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a public offering

– Financially Transformative Acquisition – – Expected to Significantly Grow Net Income, EBITDA and Operating Cash Flows – – Structure of the Financing Allows for Rapid De-Leveraging – – Provides Financial Flexibility to Pursue Future Business Development Transactions – STOUGHTON, Mass. , Feb.

– Xtampza ® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 – STOUGHTON, Mass. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today